



#14  
Dmt  
1-7-02

PATENT  
Customer No. 22,852  
Attorney Docket No. 02481.1745-00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Evi KOSTENIS

Application No.: 09/899,295

Filed: July 6, 2001

For: PROCESS FOR IDENTIFYING  
MODULATORS OF  
G-PROTEIN-COUPLED  
RECEPTORS

Group Art Unit: 1645

Examiner: Unknown

**RECEIVED**

NOV 06 2002

Assistant Commissioner for Patents  
Washington, DC 20231

TECH CENTER 1600/2900

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: November 5, 2002

By:   
Elizabeth A. Doherty  
Reg. No. 50,894

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1745-00	Application No.	09/899,295
Applicant	Evi KOSTENIS		
Filing Date	July 6, 2001	Group:	1645

## U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

RECEIVED  
NOV 06 2002  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
1	WO 99/05177	February 4, 1999	PCT	C 07 K	19/00	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

2	P. Coward, et al., "Chimeric G Proteins Allow a High-Throughput Signaling Assay of G <sub>i</sub> -Coupled Receptors," <i>Analytical Biochemistry</i> 270: 242-248 (1999).
3	J.C. Migeon, et al., "Regulation of cAMP-mediated Gene Transcription by Wild Type and Mutated G-protein $\alpha$ Subunits: Inhibition of Adenylyl Cyclase Activity by Muscarinic Receptor-Activated and Constitutively Activated G $\alpha$ ," <i>Journal of Biological Chemistry</i> 269(46): 29146-29152 (1994).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce